An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (146 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: msplacebo controlledparkinson diseaseblind placebourinary
  Phrases that lowered it: moderatemildthe effecteffect ofreceive
• Accepts healthy volunteers: No (raises risk) · Who can join
• Design: crossover (lowers risk) · Design
• Minimum age: 30 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 50.2% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 3.6% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Maximum age: 69 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, urogenital: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 172 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female NCT00679315 · started 2008 · scored riskier than 14% of active trials completed
• A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia NCT00855582 · started 2009 · scored riskier than 28% of active trials completed
• A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806) NCT00651807 · started 2008 · scored riskier than 10% of active trials terminated
• Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED NCT00790751 · started 2008 · scored riskier than 10% of active trials completed
• Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction. NCT01305083 · started 2010 · scored riskier than 51% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.